Aehr Test Systems vs Advantest: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Aehr Test Systems (AEHR)

Q3 202617 Jun – 17 Jul 2026

▲3

Aehr's AI pivot drives record bookings and a bold 2027 revenue forecast

Record bookings and AI-driven revenue forecast Aehr reported record quarterly bookings of $60.7 million and guided fiscal 2027 revenue to $130–150 million, nearly triple last year's $50 million. Management says AI processors and silicon photonics are now the main growth drivers, with 71% of revenue from AI-related chips. This directly boosts investor expectations for future sales and profits.
This is the core new event that explains the stock's surge and future growth outlook.
Earnings beat and return to profitability expected Aehr beat earnings estimates with non-GAAP EPS of $0.11 and revenue up 33% year-over-year to $18.8 million. Management expects non-GAAP net income to be 18–22% of revenue in fiscal 2027, signaling a return to profitability. This reassures investors that the company can convert strong demand into actual profits.
It shows the financial health behind the stock move and supports the bullish case.
Successful pivot from EV chips to AI processors Aehr has shifted from relying on electric-vehicle silicon carbide chips to AI accelerators, CPUs, and network processors. Two years ago, over 95% of business was EV-related; now AI chips make up 71% of revenue. This diversification reduces dependence on a single market and taps into the massive AI infrastructure buildout.
It explains the strategic transformation that is driving new orders and investor enthusiasm.
Valuation concerns and analyst caution Despite the strong news, Wall Street sees AEHR as overvalued. The consensus rating is Moderate Buy with a mean price target near $64, implying potential downside of over 40% from recent levels. The stock trades at 81 times trailing sales, so any disappointment could lead to a sharp pullback.
It provides a fair counterweight to the bullish drivers and highlights the risk for new investors.

July 202617 Jun – 17 Jul 2026

▲3

Aehr's AI pivot drives record bookings and a bold 2027 revenue forecast

Record bookings and AI-driven revenue forecast Aehr reported record quarterly bookings of $60.7 million and guided fiscal 2027 revenue to $130–150 million, nearly triple last year's $50 million. Management says AI processors and silicon photonics are now the main growth drivers, with 71% of revenue from AI-related chips. This directly boosts investor expectations for future sales and profits.
This is the core new event that explains the stock's surge and future growth outlook.
Earnings beat and return to profitability expected Aehr beat earnings estimates with non-GAAP EPS of $0.11 and revenue up 33% year-over-year to $18.8 million. Management expects non-GAAP net income to be 18–22% of revenue in fiscal 2027, signaling a return to profitability. This reassures investors that the company can convert strong demand into actual profits.
It shows the financial health behind the stock move and supports the bullish case.
Successful pivot from EV chips to AI processors Aehr has shifted from relying on electric-vehicle silicon carbide chips to AI accelerators, CPUs, and network processors. Two years ago, over 95% of business was EV-related; now AI chips make up 71% of revenue. This diversification reduces dependence on a single market and taps into the massive AI infrastructure buildout.
It explains the strategic transformation that is driving new orders and investor enthusiasm.
Valuation concerns and analyst caution Despite the strong news, Wall Street sees AEHR as overvalued. The consensus rating is Moderate Buy with a mean price target near $64, implying potential downside of over 40% from recent levels. The stock trades at 81 times trailing sales, so any disappointment could lead to a sharp pullback.
It provides a fair counterweight to the bullish drivers and highlights the risk for new investors.

Latest17 Jun – 17 Jul 2026

▲3

Aehr's AI pivot drives record bookings and a bold 2027 revenue forecast

Record bookings and AI-driven revenue forecast Aehr reported record quarterly bookings of $60.7 million and guided fiscal 2027 revenue to $130–150 million, nearly triple last year's $50 million. Management says AI processors and silicon photonics are now the main growth drivers, with 71% of revenue from AI-related chips. This directly boosts investor expectations for future sales and profits.
This is the core new event that explains the stock's surge and future growth outlook.
Earnings beat and return to profitability expected Aehr beat earnings estimates with non-GAAP EPS of $0.11 and revenue up 33% year-over-year to $18.8 million. Management expects non-GAAP net income to be 18–22% of revenue in fiscal 2027, signaling a return to profitability. This reassures investors that the company can convert strong demand into actual profits.
It shows the financial health behind the stock move and supports the bullish case.
Successful pivot from EV chips to AI processors Aehr has shifted from relying on electric-vehicle silicon carbide chips to AI accelerators, CPUs, and network processors. Two years ago, over 95% of business was EV-related; now AI chips make up 71% of revenue. This diversification reduces dependence on a single market and taps into the massive AI infrastructure buildout.
It explains the strategic transformation that is driving new orders and investor enthusiasm.
Valuation concerns and analyst caution Despite the strong news, Wall Street sees AEHR as overvalued. The consensus rating is Moderate Buy with a mean price target near $64, implying potential downside of over 40% from recent levels. The stock trades at 81 times trailing sales, so any disappointment could lead to a sharp pullback.
It provides a fair counterweight to the bullish drivers and highlights the risk for new investors.

Advantest Corp. (6857.JP)

Q3 202623 Jun – 7 Aug 2026

▲2▼2

Advantest gains on AI test demand, guidance raise; China and payback fears weigh

AI test demand and raised guidance Advantest benefits from strong demand for AI chip testing and raised its full-year net profit guidance to ¥660bn. The stock surged on robust earnings and SEMI's forecast of 23.2% equipment sales growth in 2026.
This is the main positive force behind the stock's performance in July.
Silicon photonics partnership and duopoly pricing power Advantest formed a silicon photonics partnership with OpenLight and holds duopoly pricing power with Teradyne, controlling 85–90% of the market. This strengthens its competitive position and pricing ability.
It highlights a new partnership and structural advantage supporting the stock.
AI-spending payback fears and China competition Fears that AI spending may not pay off triggered sharp selloffs, with the stock down 6–10% in July. China's chipmaking advances (Yuliangsheng, CXMT) threaten oversupply and competition, while Moonshot's open-weight AI model renewed concerns about faster Chinese progress.
These are the key risks that caused volatility and downward pressure.
Macro and cost pass-through worries Apple/Microsoft AI cost pass-through worries, Middle East tensions, and oil prices add further volatility. The stock remains highly sensitive to sentiment swings despite solid fundamentals.
These external factors contributed to price swings and investor uncertainty.

July 202623 Jun – 7 Aug 2026

▲2▼2

Advantest gains on AI test demand, guidance raise; China and payback fears weigh

AI test demand and raised guidance Advantest benefits from strong demand for AI chip testing and raised its full-year net profit guidance to ¥660bn. The stock surged on robust earnings and SEMI's forecast of 23.2% equipment sales growth in 2026.
This is the main positive force behind the stock's performance in July.
Silicon photonics partnership and duopoly pricing power Advantest formed a silicon photonics partnership with OpenLight and holds duopoly pricing power with Teradyne, controlling 85–90% of the market. This strengthens its competitive position and pricing ability.
It highlights a new partnership and structural advantage supporting the stock.
AI-spending payback fears and China competition Fears that AI spending may not pay off triggered sharp selloffs, with the stock down 6–10% in July. China's chipmaking advances (Yuliangsheng, CXMT) threaten oversupply and competition, while Moonshot's open-weight AI model renewed concerns about faster Chinese progress.
These are the key risks that caused volatility and downward pressure.
Macro and cost pass-through worries Apple/Microsoft AI cost pass-through worries, Middle East tensions, and oil prices add further volatility. The stock remains highly sensitive to sentiment swings despite solid fundamentals.
These external factors contributed to price swings and investor uncertainty.

Latest15 Jul – 7 Aug 2026

▲3▼1

Advantest rides AI test boom, strong earnings, and record equipment demand

Strong earnings revive AI chip sentiment Advantest reported stronger-than-expected earnings, triggering renewed buying in AI-related stocks and lifting the Nikkei. The results eased fears that AI spending was slowing, showing test demand for AI chips remains robust and supporting the stock's price.
This is the period's biggest company-specific catalyst, directly driving Advantest shares and the market.
Alphabet capex lifts pick-and-shovel demand Alphabet raised its capital investment plan, boosting demand for semiconductor equipment and testing. Advantest gained as a pick-and-shovel stock, since more AI data-center spending means more chips and more testing equipment needed, supporting future revenue.
It explains a key demand driver behind Advantest's gains this period.
Equipment sales forecast to grow five years SEMI forecasts global chip equipment sales rising 23.2% in 2026 to $165.9 billion, with the semiconductor market breaking $1 trillion. Analysts cite Advantest's better-than-expected results as evidence the AI-driven upcycle continues, supporting the stock.
It gives the big-picture industry backdrop confirming Advantest's growth runway.
AI selloff and China model fears hit chips A broad AI and chip selloff hit Advantest, which fell about 7% in Japan as Kioxia and Tokyo Electron plunged. China's Moonshot unveiled a powerful open-weight AI model, reinforcing fears Chinese developers are advancing faster than expected, pressuring chip stocks.
It is the main counterweight this period, showing real risk to Advantest's rally.

24 Jul – 31 Jul 2026

▲2▼2

Advantest swings on AI-spending fears, then a record profit upgrade

AI spending fears hit chip stocks Alphabet's bigger AI investment and negative cash flow sparked a global tech selloff; Advantest fell 6.33% on July 24 and about 10% on July 28 as investors questioned whether AI spending pays off.
Explains the sharp selloff that dominated the start of the period.
China chipmaking advance stokes competition Reports that China's Shanghai Yuliangsheng began mass-producing chipmaking technology long dominated by ASML, plus CXMT's debut, raised fears of Chinese capacity expansion and oversupply, dragging Advantest down with the sector.
A new competitive threat that added to the selloff pressure.
Profit forecast raised on AI test demand Advantest lifted its full-year net profit forecast to 660 billion yen from 465.5 billion, and operating profit to 846 billion yen, saying testing demand for AI inference chips is far stronger than assumed.
The core company-specific news that reversed sentiment and answers why the stock moved.
AI earnings spark record rebound Strong Microsoft and Amazon AI earnings restored confidence; Advantest surged nearly 18% on July 31 as Asian chip stocks staged a record rally, though the Kospi still ended July down 22%.
Shows the powerful recovery and the still-fragile market backdrop.

23 Jun – 9 Jul 2026

▲3

Advantest rides AI test demand, silicon photonics push, and sector swings

Silicon photonics test partnership Advantest teamed with OpenLight to build test solutions for silicon photonics, a key optical technology for AI data centers. This opens a new market for Advantest's test equipment as optical interconnects scale, supporting future revenue growth.
New partnership directly expands Advantest's addressable market in AI infrastructure.
Duopoly pricing power Advantest and Teradyne together control 85-90% of the chip test equipment market. This near-monopoly lets them keep prices high and earn strong returns, as rising chip complexity increases the amount of testing needed per chip.
Highlights structural competitive advantage that supports long-term profitability.
AI chip cost pass-through worries Apple and Microsoft raised prices on devices because AI chip costs are climbing, and their shares fell. This sparked a tech selloff that dragged Advantest down over 6% in a day, as investors feared slower demand for chips and test equipment.
Shows a real counterweight: rising costs could dampen end-demand for AI chips.
Sector rebound on AI optimism Advantest and other chip stocks rebounded as US semiconductor shares rose and investors stayed confident in long-term AI spending. Reports that China may allow limited Nvidia H200 purchases and Meta's new data center also lifted sentiment, though Middle East tensions and oil prices remain a risk.
Captures the latest positive momentum from AI investment logic and sector rotation.